Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 0/2 Study of BGB-58067, an MTA Cooperative PRMT5 Inhibitor, in Newly Diagnosed Glioblastoma Patients With Methylthioadenosine Phosphorylase (MTAP) Deleted Tumors Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With Pharmacodynamic (PD)-Triggered Expansion Cohorts

NCT07485049 is registered in ClinicalTrials.gov with Nader Sanai as lead sponsor.

NCT NCT07485049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07485049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 0/2 Study of BGB-58067, an MTA Cooperative PRMT5 Inhibitor, in Newly Diagnosed Glioblastoma Patients With Methylthioadenosine Phosphorylase (MTAP) Deleted Tumors Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With Pharmacodynamic (PD)-Triggered Expansion Cohorts
Lead sponsor
Nader Sanai
Phase
Phase 1
Overall status
Recruiting
Start date
May 7, 2026
Completion date
November 30, 2028
Enrollment
78 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma (gbm)